Antipsychotic use among persons with schizophrenia in Sweden and Finland, trends and differences

References

• Barnes TRE. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2011;25(5):567–620.
   PubMed Web of Science ®Google Scholar
• Latimer EA, Naidu A, Moodie EEM, et al. Variation in long-term antipsychotic polypharmacy and high-dose prescribing across physicians and hospitals. Psychiatr Serv. 2014;65(10):1210–1217.
   PubMed Web of Science ®Google Scholar
• Ng CH, Klimidis S. Cultural factors and the use of psychotropic medications. In: Ng C, Singh B, Chiu E, editors. Ethno-psychopharmacology: advances in current practice. Cambridge: Cambridge University Press; 2008. p. 123–134.
   Google Scholar
• Best-Shaw L, Gudbrandsen M, Nagar J, et al. Psychiatrists' perspectives on antipsychotic dose and the role of plasma concentration therapeutic drug monitoring. Ther Drug Monit. 2014;36(4):486–493.
   PubMed Web of Science ®Google Scholar
• Helbling J, Ajdacic-Gross V, Lauber C, et al. Attitudes to antipsychotic drugs and their side effects: a comparison between general practitioners and the general population. BMC Psychiatry. 2006;6(1):42.
   PubMedGoogle Scholar
• Eum S, Lee AM, Bishop JR. Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations. Dialogues Clin Neurosci. 2016;18(3):323–337.
   PubMed Web of Science ®Google Scholar
• Carbon M, Kane JM, Leucht S, et al. Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. World Psychiatry. 2018;17(3):330–340.
   PubMed Web of Science ®Google Scholar
• Kane JM. Treatment strategies to prevent relapse and encourage remission. J Clin Psychiatry. 2007;68:27–30.
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Mittendorfer-Rutz E, Majak M, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA Psychiatry. 2017;74(7):686–693.
   PubMed Web of Science ®Google Scholar
• Taylor DM, Velaga S, Werneke U. Reducing the stigma of long acting injectable antipsychotics - current concepts and future developments. Nord J Psychiatry. 2018;72(Sup1):S36–S39.
   PubMed Web of Science ®Google Scholar
• Halfdanarson Ó, Zoega H, Aagaard L, et al. International trends in antipsychotic use: study in 16 countries, 2005–2014. Eur Neuropsychopharmacol. 2017;27(10):1064–1076.
   PubMed Web of Science ®Google Scholar
• Bachmann CJ, Aagaard L, Bernardo M, et al. International trends in clozapine use: a study in 17 countries. Acta Psychiatr Scand. 2017;136(1):37–51.
   PubMed Web of Science ®Google Scholar
• Harro J, Aadamsoo K, Rootslane L, et al. Comparison of psychotropic medication use in the Baltic countries. Nord J Psychiatry. 2020;74(4):301–306.
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Haukka J, Taylor M, et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011;168(6):603–609.
   PubMed Web of Science ®Google Scholar
• Reutfors J, Brandt L, Stephansson O, et al. Antipsychotic prescription filling in patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol. 2013;33(6):759–765.
   PubMed Web of Science ®Google Scholar
• Taipale H, Mehtala J, Tanskanen A, et al. Comparative effectiveness of antipsychotic drugs for rehospitalization in schizophrenia-a nationwide study with 20-year follow-up. Schizophr Bull. 2018;44(6):1381–1387.
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Tanskanen A, Taipale H. 20-Year nationwide follow-up study on discontinuation of antipsychotic treatment in first-episode schizophrenia. Am J Psychiatry. 2018;175(8):765–773.
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Taipale H, Mehtala J, et al. Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia. JAMA Psychiatry. 2019;76(5):499–507.
   PubMed Web of Science ®Google Scholar
• Taipale H, Mittendorfer-Rutz E, Alexanderson K, et al. Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia. Schizophr Res. 2018;197:274–280.
   PubMed Web of Science ®Google Scholar
• Tanskanen A, Taipale H, Koponen M, et al. From prescription drug purchases to drug use periods – a second generation method (PRE2DUP). BMC Med Inform Decis Mak. 2015;15:21.
   PubMed Web of Science ®Google Scholar
• Suokas JT, Suvisaari JM, Haukka J, et al. Description of long-term polypharmacy among schizophrenia outpatients. Soc Psychiatry Psychiatr Epidemiol. 2013;48(4):631–638.
   PubMed Web of Science ®Google Scholar
• Votaw VR, Geyer R, Rieselbach MM, McHugh RK. The epidemiology of benzodiazepine misuse: a systematic review. Drug Alcohol Depend. 2019;200:95–114.
   PubMed Web of Science ®Google Scholar
• Dong M, Zeng L-N, Zhang Q, et al. Prescription of antipsychotic and concomitant medications for adult Asian schizophrenia patients: findings of the 2016 Research on Asian Psychotropic Prescription Patterns (REAP) survey. Asian J Psychiatr. 2019;45:74–80.
   PubMed Web of Science ®Google Scholar
• Toto S, Grohmann R, Bleich S, et al. Psychopharmacological treatment of schizophrenia over time in 30 908 inpatients: data from the AMSP study. Int J Neuropsychopharmacol. 2019;22(9):560–573.
   PubMed Web of Science ®Google Scholar
• SOCIALSTYRELSEN. Nationella riktlinjer för antipsykotisk läkemedelsbehandling vid schizofreni och schizofreniliknande tillstånd. Artik. 2014-4-6. 2014. Available from: www.socialstyrelsen.se.
   Google Scholar
• Duodecim FMS. Current care guideline on schizophrenia. Published Online First: 2015. Available from: http://www.kaypahoito.fi/.
   Google Scholar
• Tiihonen J, Mittendorfer-Rutz E, Torniainen M, et al. Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: an observational follow-up study. Am J Psychiatry. 2016;173(6):600–606.
   PubMed Web of Science ®Google Scholar
• Taipale H, Tanskanen A, Mehtala J, et al. 20-Year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). World Psychiatry. 2020;19(1):61–68.
   PubMed Web of Science ®Google Scholar